biotech / news / / CNBC
Eli Lilly agrees to buy Curevo, LimmaTech Biologics and Vaccine Company.
Eli Lilly will acquire Curevo, LimmaTech Biologics, and Vaccine Company for nearly $4 billion total.
KEY POINTS
- The deals include $1.5 billion for Curevo, $780 million for LimmaTech Biologics, and $1.55 billion for Vaccine Company.
- These acquisitions mark a strategic expansion into infectious disease research and development for Eli Lilly.
- Eli Lilly shares increased by 1.3% in premarket trading following the acquisition announcements.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →